November SMC decisions
The Scottish Medicines Consortium (SMC) has published its November 2014 decisions on medicines to be used in NHS Scotland. Aflibercept (Eylea), daclatasvir (Daklinza), everolimus (Afinitor), ipilimumab (Yervoy) and saxagliptin (Onglyza) have been recommended for use in NHS Scotland. Pertuzumab (Perjeta) has been rejected for use in NHS Scotland. Further information is available on the SMC’s website in the November 2014 briefing note.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067169
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com